A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

Alfredo Pece; Paolo Milani; Carla Monteleone; Costantino John Trombetta; Giuseppe De Crecchio; Giuseppe Fasolino; Domenica Matranga; Salvatore Cillino; Maria Vadalà

doi:10.1007/s00417-014-2886-x

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

Alfredo Pece, Paolo Milani, Carla Monteleone, Costantino John Trombetta, Giuseppe De Crecchio, Giuseppe Fasolino, Domenica Matranga, Salvatore Cillino, Maria Vadalà

Ophthalmology - Eye surgery

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM).

METHODS: This was a prospective multicenter randomized nonblinded trial.

RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was 0.52 logMAR (20/63 Seq) and 54 ls, and final BCVA was 0.51 logMar (20/63 Seq) and 57 ls. In group R, mean basal BCVA was 0.62 logMAR (20/80 Seq) and 45 ls, and the final values were 0.50 logMAR (20/63 Seq) and 58 ls. Statistical comparison of the two groups showed no significant difference (logMAR p = 0.90 and letters p = 0.78). Multivariate analysis showed no influence of age or previous photodynamic treatment (PDT) on final visual changes. The mean number of treatments in the first year was 2.7 in group B and 2.3 in group R (p = 0.09).

CONCLUSION: Myopic CNV equally benefits from on-demand intravitreal injection of either bevacizumab or ranibizumab; the therapeutic effect is independent of previous PDT and age.

Original language	English
Pages (from-to)	1867-1872
Number of pages	6
Journal	Graefe's Archive for Clinical and Experimental Ophthalmology
Volume	253
Issue number	11
DOIs	https://doi.org/10.1007/s00417-014-2886-x
Publication status	Published - Nov 2015

Keywords

Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors/therapeutic use
Bevacizumab/therapeutic use
Choroidal Neovascularization/drug therapy
Female
Follow-Up Studies
Humans
Intravitreal Injections
Male
Middle Aged
Myopia, Degenerative/drug therapy
Prospective Studies
Ranibizumab/therapeutic use
Vascular Endothelial Growth Factor A/antagonists & inhibitors
Visual Acuity/drug effects

Access to Document

10.1007/s00417-014-2886-x

Cite this

Pece, Alfredo ; Milani, Paolo ; Monteleone, Carla ; Trombetta, Costantino John ; De Crecchio, Giuseppe ; Fasolino, Giuseppe ; Matranga, Domenica ; Cillino, Salvatore ; Vadalà, Maria. / A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. In: Graefe's Archive for Clinical and Experimental Ophthalmology. 2015 ; Vol. 253, No. 11. pp. 1867-1872.

@article{09551c5399514d0bb41215e8d7884277,

title = "A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV",

abstract = "AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM).METHODS: This was a prospective multicenter randomized nonblinded trial.RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an {"}on demand{"} regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was 0.52 logMAR (20/63 Seq) and 54 ls, and final BCVA was 0.51 logMar (20/63 Seq) and 57 ls. In group R, mean basal BCVA was 0.62 logMAR (20/80 Seq) and 45 ls, and the final values were 0.50 logMAR (20/63 Seq) and 58 ls. Statistical comparison of the two groups showed no significant difference (logMAR p = 0.90 and letters p = 0.78). Multivariate analysis showed no influence of age or previous photodynamic treatment (PDT) on final visual changes. The mean number of treatments in the first year was 2.7 in group B and 2.3 in group R (p = 0.09).CONCLUSION: Myopic CNV equally benefits from on-demand intravitreal injection of either bevacizumab or ranibizumab; the therapeutic effect is independent of previous PDT and age.",

keywords = "Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors/therapeutic use, Bevacizumab/therapeutic use, Choroidal Neovascularization/drug therapy, Female, Follow-Up Studies, Humans, Intravitreal Injections, Male, Middle Aged, Myopia, Degenerative/drug therapy, Prospective Studies, Ranibizumab/therapeutic use, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Visual Acuity/drug effects",

author = "Alfredo Pece and Paolo Milani and Carla Monteleone and Trombetta, {Costantino John} and {De Crecchio}, Giuseppe and Giuseppe Fasolino and Domenica Matranga and Salvatore Cillino and Maria Vadal{\`a}",

year = "2015",

month = nov,

doi = "10.1007/s00417-014-2886-x",

language = "English",

volume = "253",

pages = "1867--1872",

journal = "Graefe's Archive for Clinical and Experimental Ophthalmology",

issn = "0721-832X",

publisher = "Springer Verlag",

number = "11",

}

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV. / Pece, Alfredo; Milani, Paolo; Monteleone, Carla; Trombetta, Costantino John; De Crecchio, Giuseppe; Fasolino, Giuseppe; Matranga, Domenica; Cillino, Salvatore; Vadalà, Maria.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 253, No. 11, 11.2015, p. 1867-1872.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

AU - Pece, Alfredo

AU - Milani, Paolo

AU - Monteleone, Carla

AU - Trombetta, Costantino John

AU - De Crecchio, Giuseppe

AU - Fasolino, Giuseppe

AU - Matranga, Domenica

AU - Cillino, Salvatore

AU - Vadalà, Maria

PY - 2015/11

Y1 - 2015/11

N2 - AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM).METHODS: This was a prospective multicenter randomized nonblinded trial.RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was 0.52 logMAR (20/63 Seq) and 54 ls, and final BCVA was 0.51 logMar (20/63 Seq) and 57 ls. In group R, mean basal BCVA was 0.62 logMAR (20/80 Seq) and 45 ls, and the final values were 0.50 logMAR (20/63 Seq) and 58 ls. Statistical comparison of the two groups showed no significant difference (logMAR p = 0.90 and letters p = 0.78). Multivariate analysis showed no influence of age or previous photodynamic treatment (PDT) on final visual changes. The mean number of treatments in the first year was 2.7 in group B and 2.3 in group R (p = 0.09).CONCLUSION: Myopic CNV equally benefits from on-demand intravitreal injection of either bevacizumab or ranibizumab; the therapeutic effect is independent of previous PDT and age.

AB - AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM).METHODS: This was a prospective multicenter randomized nonblinded trial.RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was 0.52 logMAR (20/63 Seq) and 54 ls, and final BCVA was 0.51 logMar (20/63 Seq) and 57 ls. In group R, mean basal BCVA was 0.62 logMAR (20/80 Seq) and 45 ls, and the final values were 0.50 logMAR (20/63 Seq) and 58 ls. Statistical comparison of the two groups showed no significant difference (logMAR p = 0.90 and letters p = 0.78). Multivariate analysis showed no influence of age or previous photodynamic treatment (PDT) on final visual changes. The mean number of treatments in the first year was 2.7 in group B and 2.3 in group R (p = 0.09).CONCLUSION: Myopic CNV equally benefits from on-demand intravitreal injection of either bevacizumab or ranibizumab; the therapeutic effect is independent of previous PDT and age.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors/therapeutic use

KW - Bevacizumab/therapeutic use

KW - Choroidal Neovascularization/drug therapy

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Intravitreal Injections

KW - Male

KW - Middle Aged

KW - Myopia, Degenerative/drug therapy

KW - Prospective Studies

KW - Ranibizumab/therapeutic use

KW - Vascular Endothelial Growth Factor A/antagonists & inhibitors

KW - Visual Acuity/drug effects

U2 - 10.1007/s00417-014-2886-x

DO - 10.1007/s00417-014-2886-x

M3 - Article

C2 - 25500986

VL - 253

SP - 1867

EP - 1872

JO - Graefe's Archive for Clinical and Experimental Ophthalmology

JF - Graefe's Archive for Clinical and Experimental Ophthalmology

SN - 0721-832X

IS - 11

ER -

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

Abstract

Keywords

Access to Document

Fingerprint

Cite this